OrbiMed Disposes of $39 Million Enliven Therapeutics Shares Amid 130% Surge

On June 22, 2026, Orbimed Advisors, a 10% shareholder of Enliven Therapeutics, Inc. (NASDAQ:ELVN), announced the indirect sale of 860,123 shares, valued at roughly $39.0 million, per an SEC Form 4 filing.

Transaction summary

Transaction value derived from the SEC Form 4 weighted‑average purchase price of $45.36; post‑transaction value calculated using the June 22, 2026 closing market price.

Key questions

• What is the structure of OrbiMed’s ownership post-transaction?
  After the transaction, the remaining 6,555,102 shares are held indirectly via OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, L.P.

• What proportion of total holdings was impacted by this transaction?
  The sale accounted for 11.60% of Advisors LLC Orbimed’s prior indirect holdings, representing a notable reduction in its overall stake but not a complete exit.

• How does current trading context relate to the transaction price?
  The shares were sold at approximately $45.36 each, near the $45.96 closing price on June 22, 2026, and the stock rose to $50 by June 26, 2026, reflecting modest post‑sale appreciation.

Company overview

1‑year performance is calculated using June 22, 2026 as the reference date.

Company snapshot

• Enliven Therapeutics is advancing a pipeline of small‑molecule kinase inhibitors, with lead candidates ELVN‑001 (targeting chronic myeloid leukemia) and ELVN‑002 (targeting HER2‑mutant cancers) currently in Phase 1 trials.

• The company relies on a research‑driven model, seeking future revenue through the development, regulatory approval, and commercialization or licensing of its oncology drug candidates.

• Its primary target market comprises adult cancer patients, particularly those with chronic myeloid leukemia or HER2‑driven malignancies, as well as the healthcare providers and institutions that treat them.

Story Continues

What this transaction means for investors

Even after reducing its position by roughly 860,000 shares, OrbiMed continues to hold over 6.5 million shares indirectly, signaling continued confidence despite taking partial profits following the stock’s approximately 130% gain over the past year.

The company’s outlook depends on clinical execution. Earlier this month, it released updated positive Phase 1 ENABLE trial data for ELVN‑001, and in May, Enliven reaffirmed its plan to initiate the pivotal Phase 3 ENABLE‑2 trial in the second half of the year. CEO Rick Fair noted that recent momentum in the CML market “validates an unmet need and a compelling long‑term opportunity,” adding that management believes ELVN‑001 could become a best‑in‑class therapy. The biotech ended the first quarter with $452.4 million in cash, cash equivalents, and marketable securities, which it expects to fund operations through the first half of 2029.

The balance sheet has meanwhile been bolstered further. Earlier this month, Enliven closed an upsized public offering that raised roughly $460 million in gross proceeds, providing additional capital to advance its pipeline.

For long‑term investors, OrbiMed’s sale merits attention, but Enliven’s clinical milestones, cash position, and execution are far more decisive drivers of the stock than any single institutional transaction.

Source link